Lupus is more common in Black people, and symptoms can be different too. Here's what to look out for and how to treat it.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Chronic kidney disease (CKD), often described as a “quiet disease”, progresses silently and is frequently detected only after significant kidney damage has occurred, prompting experts to urge women to ...

Chronic kidney disease (CKD), often described as a "quiet disease", progresses silently and is frequently detected only after significant kidney damage has occurred, prompting experts to urge women to ...

All that’s needed now, they say, is political will to get the reforms into practice. “We really do have a mandate to change,” said Kidney Health Australia chief executive Chris Forbes. “We can give ...

Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.

Leerink Global Healthcare Conference 2026 March 10, 2026 1:00 PM EDTCompany ParticipantsUptal Patel - Chief Medical ...

A machine learning-driven framework accurately predicts MPA exposure and supports individualized dosing in childhood-onset LN.

Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company’s near- and mid-term priorities at the Leerink Partners Global Healthcare Conference, emphasizing the commercialization of its anemia ...

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...

Roche Holding AG ( RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline March 9, 2026 12:00 PM EDT ...

Major risk factors include Diabetes mellitus, hypertension, cardiovascular disease, obesity, family history of kidney disease, etc.